The Calreticulin pipeline drugs market research report outlays comprehensive information on the Calreticulin targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Calreticulin pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Calreticulin - Drugs In Development, 2024

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers products from therapy areas such as Oncology, Ophthalmology, and Gastrointestinal which include the indications Myeloproliferative Disorders, Essential Thrombocythemia, Choroidal Neovascularization, and Inflammatory Bowel Disease. It also reviews key players involved in Calreticulin targeted therapeutics development with respective active and dormant or discontinued products.

The Calreticulin pipeline targets constitutes close to eight molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 2, 1, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 3 molecule.

Calreticulin overview

Calreticulin is a protein that in humans is encoded by a gene CALR. It is also known as calregulin, calsequestrin-like protein, and endoplasmic reticulum resident protein 60 (ERp60). CALR is involved in a variety of cellular processes mainly in cell adhesion, protein folding quality control and calcium homeostasis. Calreticulin is also found in the nucleus, suggesting that it may have a role in transcription regulation. Systemic lupus erythematosus is associated with increased autoantibody titers against calreticulin. Recurrent mutations in calreticulin have been linked to various neoplasms, including the myeloproliferative type.

For a complete picture of Calreticulin’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.